Dysregulation of BMP9/BMPR2/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats | Zendy

Jiang Qian | Zendy; Liu Chunli | Zendy; Liu Shiyun | Zendy; Lu Wenju | Zendy; Li Yi | Zendy; Luo Xiaoyun | Zendy; Ma Ran | Zendy; Zhang Chenting | Zendy; Chen Haixia | Zendy; Chen Yuqin | Zendy; Zhang Zizhou | Zendy; Hong Cheng | Zendy; Guo Wenliang | Zendy; Wang Tao | Zendy; Yang Kai | Zendy; Wang Jian | Zendy

Premium

Dysregulation of BMP9/BMPR2/SMAD signalling pathway contributes to pulmonary fibrosis and pulmonary hypertension induced by bleomycin in rats

Author(s) -

Jiang Qian,

Liu Chunli,

Liu Shiyun,

Lu Wenju,

Li Yi,

Luo Xiaoyun,

Ma Ran,

Zhang Chenting,

Chen Haixia,

Chen Yuqin,

Zhang Zizhou,

Hong Cheng,

Guo Wenliang,

Wang Tao,

Yang Kai,

Wang Jian

Publication year - 2021

Publication title -

british journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.432

H-Index - 211

eISSN - 1476-5381

pISSN - 0007-1188

DOI - 10.1111/bph.15285

Subject(s) - pulmonary fibrosis , pulmonary hypertension , bleomycin , bmpr2 , smad , medicine , fibrosis , signal transduction , bone morphogenetic protein , endocrinology , transforming growth factor , chemistry , microbiology and biotechnology , biology , biochemistry , chemotherapy , gene

Pulmonary hypertension related to pulmonary fibrosis is classed as WHO Group III, one of the most common groups which lacks effective treatment options. In this study, we aimed to uncover the underlying mechanisms, particularly the involvement of the BMP9/BMPR2/SMAD signalling pathway, in this subtype of pulmonary hypertension.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research